Tularemia vaccine: Safety, reactogenicity, “Take” skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain – A phase 2 randomized clinical Trial
Mark J. Mulligan(New York University), Johannes B. Goll(J. Craig Venter Institute), Marcelo B. Sztein(University of Maryland, Baltimore), Srilatha Edupuganti(Emory University), Jack T. Stapleton(University of Iowa), Samer S. El‐Kamary(University of Maryland, Baltimore), Hana M. El Sahly(Baylor College of Medicine), Nadine Rouphael(Emory University), Patricia Winokur(University of Iowa), Irene Graham(Saint Louis University), Sharon E. Frey(St. Louis VA Medical Center), Shital M. Patel(Baylor College of Medicine), Allison Beck, Marcela F. Pasetti(University of Maryland Global Campus), Edwin L. Anderson, Heather Hill(Emmes (United States)), Robert L. Atmar(Baylor College of Medicine), Wendy A. Keitel(Baylor College of Medicine), Wilbur H. Chen(University of Maryland, Baltimore)
Cited by 37
Related Papers
A framework for human microbiome research
|Nature|2012|2.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k